PL1806136T3 - Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego - Google Patents
Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowegoInfo
- Publication number
- PL1806136T3 PL1806136T3 PL05790245T PL05790245T PL1806136T3 PL 1806136 T3 PL1806136 T3 PL 1806136T3 PL 05790245 T PL05790245 T PL 05790245T PL 05790245 T PL05790245 T PL 05790245T PL 1806136 T3 PL1806136 T3 PL 1806136T3
- Authority
- PL
- Poland
- Prior art keywords
- group
- prevention
- transition
- optionally substituted
- medicinal composition
- Prior art date
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title abstract 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 230000007704 transition Effects 0.000 title abstract 3
- 201000004240 prostatic hypertrophy Diseases 0.000 title 1
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004294358 | 2004-10-06 | ||
| JP2005160843 | 2005-06-01 | ||
| EP05790245A EP1806136B1 (en) | 2004-10-06 | 2005-10-04 | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy |
| PCT/JP2005/018356 WO2006038619A1 (ja) | 2004-10-06 | 2005-10-04 | 前立腺肥大症に対する手術療法への移行予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1806136T3 true PL1806136T3 (pl) | 2012-04-30 |
Family
ID=36142692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05790245T PL1806136T3 (pl) | 2004-10-06 | 2005-10-04 | Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080090893A1 (pl) |
| EP (1) | EP1806136B1 (pl) |
| JP (1) | JPWO2006038619A1 (pl) |
| KR (1) | KR20070059152A (pl) |
| AT (1) | ATE535242T1 (pl) |
| CA (1) | CA2582045C (pl) |
| ES (1) | ES2378240T3 (pl) |
| PL (1) | PL1806136T3 (pl) |
| PT (1) | PT1806136E (pl) |
| SI (1) | SI1806136T1 (pl) |
| TW (1) | TWI377058B (pl) |
| WO (1) | WO2006038619A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106536A1 (en) * | 2007-02-28 | 2008-09-04 | Kissei Pharmaceuticals Co., Ltd. | Use of silodosin in a once daily administration for treating benign prostatic hyperplasia |
| CA2697137A1 (en) * | 2007-07-20 | 2009-01-29 | Astellas Pharma Inc. | Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly |
| EP2181707A1 (en) * | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| WO2012000926A1 (de) * | 2010-06-28 | 2012-01-05 | Ratiopharm Gmbh | Silodosin-cyclodextrin einschlussverbindungen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015202A1 (fr) * | 1997-09-22 | 1999-04-01 | Kissei Pharmaceutical Co., Ltd. | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate |
| PT1293198E (pt) * | 2001-09-14 | 2005-06-30 | Kissei Pharmaceutical Co Lda | Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario |
| US20030225079A1 (en) * | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
| UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
| BRPI0404050A (pt) * | 2003-09-24 | 2005-06-14 | Bioxell Spa | Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento |
| US20070167511A1 (en) * | 2004-03-05 | 2007-07-19 | Kissei Pharmaceutical Co,. Ltd. | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
-
2005
- 2005-10-04 AT AT05790245T patent/ATE535242T1/de active
- 2005-10-04 KR KR1020077008738A patent/KR20070059152A/ko not_active Ceased
- 2005-10-04 EP EP05790245A patent/EP1806136B1/en not_active Expired - Lifetime
- 2005-10-04 ES ES05790245T patent/ES2378240T3/es not_active Expired - Lifetime
- 2005-10-04 CA CA2582045A patent/CA2582045C/en not_active Expired - Lifetime
- 2005-10-04 PT PT05790245T patent/PT1806136E/pt unknown
- 2005-10-04 PL PL05790245T patent/PL1806136T3/pl unknown
- 2005-10-04 SI SI200531474T patent/SI1806136T1/sl unknown
- 2005-10-04 JP JP2006539298A patent/JPWO2006038619A1/ja active Pending
- 2005-10-04 US US11/576,800 patent/US20080090893A1/en not_active Abandoned
- 2005-10-04 WO PCT/JP2005/018356 patent/WO2006038619A1/ja not_active Ceased
- 2005-10-06 TW TW094134936A patent/TWI377058B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200626143A (en) | 2006-08-01 |
| EP1806136A1 (en) | 2007-07-11 |
| CA2582045A1 (en) | 2006-04-13 |
| ATE535242T1 (de) | 2011-12-15 |
| EP1806136A4 (en) | 2008-03-12 |
| US20080090893A1 (en) | 2008-04-17 |
| WO2006038619A1 (ja) | 2006-04-13 |
| PT1806136E (pt) | 2012-03-08 |
| KR20070059152A (ko) | 2007-06-11 |
| CA2582045C (en) | 2013-10-22 |
| SI1806136T1 (sl) | 2012-03-30 |
| ES2378240T3 (es) | 2012-04-10 |
| TWI377058B (en) | 2012-11-21 |
| JPWO2006038619A1 (ja) | 2008-05-15 |
| EP1806136B1 (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| NO20060971L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| NO20050016L (no) | Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| IL149163A0 (en) | Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them | |
| UA84146C2 (ru) | Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| NO20051527D0 (no) | 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer. | |
| WO2003000695A8 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| IL173032A0 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| WO2003053368A3 (en) | Chalcone derivatives and their use to treat diseases | |
| WO2001064642A3 (en) | Benzamides and related inhibitors of factor xa | |
| PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
| PT1452524E (pt) | Derivado de 2-oxo-1-pirrolidina e suas utilizações farmacêuticas | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
| NO20015172L (no) | 1-metyl-erytromycin-derivater | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| MXPA05006889A (es) | Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. | |
| SE0402925D0 (sv) | Novel Compounds |